Sign in
CompletedNo phase

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Key facts

Who runs it
Denali Therapeutics Inc.
Where
Chapel Hill, Oakland, and Pittsburgh, United StatesSee the 3 sitesAlso in 2 other countries, 3 sites
Trial code
Status
Completed
People taking part
18 people enrolled
Started
23 Oct 2019
Ended
1 Mar 2024
Type of study
Observational, 6 groups
Record updated
10 June 2024

Who can take part

Age
Up to 30 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Participants aged 2 through 10 years
  • nMPS II subgroup: participants with a development quotient (DQ) <85 and/or a decline of at least 7.5 points in DQ, assessed at least 6 months apart, or with the same genetic mutation as a blood relative with confirmed nMPS II
  • Participants aged 2 through 30 years
  • nMPS II subgroup: patients with an age-adjusted DQ <85 and/or a decline of 10 points or more in DQ in the previous 6 months or more, or with the same genetic mutation as a blood relative with confirmed nMPS II
  • Scheduled to undergo general anesthesia or CSF sampling for non-study-related medical reasons and parent(s)/legally authorized representative consent to donate CSF for research purposes during that procedure, or an adult patient is able to provide consent and agrees to participation in the study for CSF collection/donation
  • nMPS II participants aged <8 years
  • nnMPS II participants aged 6 to 17 years
  • Participants aged ≤ 3 years
  • Have undetermined MPS II phenotype; Do not have a large deletion(s) or rearrangement(s) in the IDS gene or other definitive mutation indicative of nMPS II; Do not have a DQ < 85 at the screening/baseline neurocognitive assessment and/or a documented decline of at least 7.5 points in DQ in the previous 6 to 18 months; Do not have the same IDS gene variant as a blood relative with confirmed nMPS II or nnMPS II
  • nMPS II participants aged 1 to 17 years
  • Have received an MPS II gene therapy or allogeneic HSCT > 12 months prior to screening
  • Have a post-HSCT or post-gene therapy DQ < 85 at the screening/baseline neurocognitive assessment and/or a documented decline of at least 7.5 points in DQ in the previous 6 to 18 months

Who cannot take part

  • Have received any central nervous system (CNS)-targeted MPS II investigational therapy within the previous 6 months
  • Have unstable medical condition that would make participation in the study unsafe or would interfere with necessary medical care

Where in United States

Also in 2 other countries, 3 sites

  • UNC Children's Research InstituteChapel Hill, United States
  • UCSF Benioff Children s HospitalOakland, United States
  • UPMC Children's Hospital of PittsburghPittsburgh, United States

About the trial

What the trial wants to find out

This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of disease in participants with MPS II who are aged ≤30 years at the time of enrollment.

The 6 groups in the trial

  • Part 1

    Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 2

    Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical outcome assessments are optional in Part 2 for participants aged 18 years or younger; no clinical assessments are planned for participants older than 18 years.

  • Part 3

    Participants \<8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 4

    Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 5

    Participants ≤3 years of age with an undetermined MPS II phenotype. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 6

    Participants from 1 to 17 years of age with nMPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted. Part 6 will also include a single collection of CSF.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
Record updated
10 June 2024